This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BridgeBio Pharma raised $299.2mm through a late-stage venture round co-led by existing investors KKR and Viking Global Investors. Returning backers Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital also participated, along with first-time buyers Sequoia Capital and an undisclosed blue-chip long-term investor. BridgeBio is developing treatments for rare genetic diseases and will use the proceeds to support activities related to its pipeline of over 15 candidates in the areas of dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Drug Discovery Tools
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?